Mining And Ores Tenders

Conclusion of a Non-Exclusive Framework Agreement for Control Tests and Preliminary Investigations in the Open House Procedure of the Southwest Branch, Published in 2023

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Teriparatide (H05aa02) as Part of a So-Called Open House Model.

Open House Contracts for Several Active Ingredients/Combinations of Active Ingredients

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Piribedil (N04bc08) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Purposes Described in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open Hous...

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredients Formoterol and Fluticasone (R03ak11) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Tamoxifen (L02ba01) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicinal Products with the Active Ingredient Natalizumab (L04aa23), S.C. Dosage Form as Part of an Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for the Purposes Described in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open Hous...

Open House Originals Discount Agreements 2023-34 - Abemaciclib